GLP-1 Medications for Obesity (BMI 30+): Clinical Evidence, Options & How Tmates Can Help

Who Qualifies as Obese for GLP-1 Therapy?

The clinical definition of obesity is BMI ≥30. This is the primary eligibility criterion used in the STEP-1 (semaglutide) and SURMOUNT-1 (tirzepatide) clinical trials, and it is the criterion your Tmates physician applies when reviewing your intake. If your BMI is ≥30, you meet the primary weight-based eligibility criterion for GLP-1 treatment through Tmates telehealth — subject to physician review of your complete health history for contraindications.

Adults with BMI 27–29.9 (overweight, not obese) also qualify for GLP-1 therapy when at least one weight-related health condition is present: type 2 diabetes, hypertension, high cholesterol, sleep apnea, or cardiovascular disease. The semaglutide program at $249/mo and tirzepatide program at $297/mo are available to both BMI populations with physician evaluation.

Why GLP-1 Medications Produce Results Dieting Cannot

Obesity is not a character or willpower problem — it is a biological condition involving leptin resistance, chronically elevated ghrelin, and blunted GLP-1 signaling that makes hunger persistent and strong regardless of caloric intake. This biology is why diet-only approaches produce average weight regain of 80–85% of lost weight within 5 years for most people: the body's hormonal systems actively resist and reverse caloric restriction through mechanisms outside conscious control.

GLP-1 medications work directly on the biology: they suppress appetite through hypothalamic receptor agonism, slow gastric emptying so fullness persists longer after meals, and eliminate the food noise that makes caloric restriction feel like constant willpower expenditure. This is why Tmates' telehealth approach's GLP-1 programs produce the results they do: 14.9% average weight loss (semaglutide, STEP-1) and 22.5% average weight loss (tirzepatide, SURMOUNT-1). These aren't diet results augmented by medication — they are pharmacological outcomes that diet alone cannot replicate.

For specific metabolic conditions: GLP-1 for metabolic syndrome, GLP-1 for PCOS, GLP-1 for prediabetes. Compare treatment options in the weight loss category and see semaglutide vs tirzepatide for head-to-head analysis. Read the full Tmates review 2026 and complete GLP-1 medications guide. See how Tmates works.

The long-term commitment: Clinical evidence consistently shows that most patients regain significant weight after stopping GLP-1 medications — similar to the pattern seen with all effective obesity medications. This supports viewing GLP-1 therapy as ongoing management rather than a finite course. The 12-month tirzepatide bundle at $167/mo and semaglutide at $158/mo make long-term treatment more financially sustainable. Your Tmates physician discusses the appropriate treatment timeline during your care relationship.